Raj Chovatiya, MD, PhD; Erin Michael , 2025-04-17 18:56:00
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting.
The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
“When taking a look at the data, it was seen that individuals actually were able to achieve pretty high rates of PASI 90 or PASI 100,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at